VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's first quarter 2022 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key followed by the number one on your touchtone phone. If you'd like to withdraw your question, press star followed by the number two. if you're using speaker equipment please lift the handset before making your selection this conference call is being recorded today may 12 2022 and now i'd like to turn the conference call over to scott powell executive vice president of investor relations please go ahead thank you and welcome everyone to today's earnings conference call for volition rx limited this call will cover volition's financial

and operating results for the first quarter of 2022, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. Also on our call today is Mr. Cameron Reynolds, President and Chief Executive Officer, Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary, and Mr. Terry Cuse, Chief Financial Officer. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. I'd now like to turn the call over to our President and Chief Executive Officer, Mr. Cameron Reynolds. Cameron?

Thanks, Scott, and thank you, everyone, for joining Volition's first quarter 2022 earnings call today. We especially appreciate your time, given the busy earnings call season. We will commence the call with our financial report, and then, given all the activities surrounding Volition Vet, we are delighted to be joined by Dr. Tom Batera, Chief Executive Officer of Volition Veterinary. And then I will wrap up with a quick update of our exciting ongoing work. But first, an advertisement. Just in case you missed previous announcements, we are hosting our 2022 Capital Markets Day tomorrow, May 13th, at 10 a.m. U.S. Eastern Time. You might just be in time to register to attend in person at the NYIC, or else you are very welcome to join via the webcast. Details for both can be found on our website, volition.com, in the investor relations section. Given the capital markets presentation tomorrow, and indeed the fairly recent filing of the 10K, we aim to keep this call quite tight, but as usual, we'll be happy to answer any questions you might have. And with that, I will hand over to Tarek for our financial update.